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INTERVAL HIGH-DOSAGE VITAMIN D THERAPY IN PATIENTS WITH 
INFLAMMATORY BOWEL DISEASE 
 
DIANA ZHENG 
 
ABSTRACT 
Existing data have demonstrated that adequate levels of vitamin D are not only 
important for bone health but also support the development and maintenance of the immune 
system. As such, vitamin D sufficiency may be important in controlling the mucosal 
inflammation observed in patients with inflammatory bowel disease (IBD). Dietary intake 
of sufficient vitamin D can be daunting for many patients, and compliance with daily 
vitamin D supplements a challenge.  As such, the goal of this project is to assess the safety 
and efficacy of high-dose oral interval vitamin D therapy in children and young adults with 
IBD.   We chose to study this hypothesis in patients treated with Remicade (infliximab), 
which necessitates regular (monthly or bimonthly) office visits.  Patients are eligible if they 
are being treated with Remicade, have a documented 25-hydroxyvitamin D less than 
30.0ng/mL within 8 weeks of enrollment, and do not have a history of an underlying renal 
or liver disease that would complicate the assessment of potential adverse effects of study 
therapy.  
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INTRODUCTION 
 
Vitamin D Purpose and Significance  
 The role played by vitamin D in regulating calcium and phosphate homeostasis, as 
well as bone health, is well-documented in the literature. More recent studies have 
demonstrated the presence of vitamin D receptors (VDRs) in non-skeletal cells throughout 
the body, and this suggests that vitamin D activity likely extends beyond a narrow scope 
of preventing rickets and osteomalacia (Ross, 2011). It is now known that vitamin D 
physiology includes anti-proliferative, cancer-preventative, as well as anti-inflammatory 
effects (Garland, 2011; Ross, 2011).  
 Vitamin D exists in two forms: ergocalciferol (vitamin D2) and cholecalciferol 
(vitamin D3).  Both forms are available in foods and dietary supplements. Vitamin D3 binds 
more strongly to VDR, which increases its bioactivity (Bikle, 2014).  However, the net 
anabolic effect of vitamins D2 and D3 do not differ significantly (Hammami, 2017). 
Vitamin D is fat-soluble and readily absorbed from the lumen of the small intestines and 
into the lymphatics with other emulsified and digested fats. Consequently, vitamin D is 
most efficiently absorbed when administered within the context of a lipid-rich meal 
(Dawson-Hughes, 2015). Small bowel mucosal dysfunction can have an impact on vitamin 
D absorption.  However, due to the compensatory length of the small intestine, localized 
regional inflammation, such as that occurring in patients with Crohn disease, it is unlikely 
to impact significantly on a patient’s ability to absorb sufficient amounts of vitamin D 
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(Ross, 2011). As such, the absorption of vitamin D does not differ significantly when 
compared in patients with IBD and healthy controls. 
7-dehydrocholesterol, the precursor molecule that is converted to pre-vitamin D3 in 
the epidermis following ultraviolet B radiation from the sun, is produced by the liver (Ross, 
2011). Calciferol, the precursor molecule of vitamin D, is a prohormone and must undergo 
sequential hydroxylations to become the active metabolite calcitriol. Both the liver and the 
kidneys play crucial roles in vitamin D conversion and thus vitamin D sufficiency (Bikle, 
2014). The liver enzyme 25-hydroxylase converts vitamin D2 or D3 into 25-
hydroxyvitamin D (25OHD), the primary circulating form of vitamin D. Lack of 
conversion of 25OHD into the active metabolite calcitriol will result in a functional vitamin 
D deficiency. When serum calcium levels decrease, parathyroid hormone will rise, 
triggering the kidney to synthesize 1a-hydroxylase, which converts circulating 25OHD 
into calcitriol. As such, diseases of both the liver and kidney can have a major impact on 
the ability of vitamin D to maintain bone health and support the immune system (Pappa, 
2011; El-Matary, 2011).  
The recommended daily intake of vitamin D is between 1,000 and 2,000 IU (Ross 
AC, 2011). Note that 40IU of vitamin D is equivalent to 1 µg, according to the National 
Institute of Health (NIH, 2018). A 25OHD level of 20ng/mL is considered sufficient to 
prevent rickets (Pappa, 2011).  However, a minimum level of 32ng/mL is requisite to 
maximize transport of dietary calcium across the intestinal epithelium. Although chronic 
vitamin D deficiency results in the bone pathology termed rickets, pathology related to 
supra-therapeutic levels of vitamin D is less common. Treatment regimens for 
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hypovitaminosis D in pediatric patients typically involve doses in the range of 50,000 IU 
per week (Jørgenson, 2010).     
 Vitamin D activity is regulated at the level of conversion between the inactive 
25OHD and calcitriol (Alsharani, 2013). As such, relatively high doses of vitamin D has 
not demonstrated significant toxicity in previous studies.  Vitamin D is a fat-soluble 
vitamin that is readily stored in adipose tissues. As such, patients with higher BMI may be 
less responsive to treatment for vitamin D deficiency (Lagunova, 2009).  This suggests that 
patients with higher BMI (and subsequently more adipose tissue) will be likely to require 
more in the way of vitamin D supplementation to achieve sufficiency.  Calcitriol levels are 
regulated by compensatory increases in 24-hydroxylase levels. This enzyme, synthesized 
ubiquitously, hydroxylates and thereby polarizes calcitriol into an inactive form that is 
unable to pass the plasma membrane and be active in circulation (Bikle, 2014).  
 
Inflammatory Bowel Disease: Crohn Disease and Ulcerative Colitis 
 IBD is an autoimmune disease of the small and large bowel. The etiology of IBD 
remains unclear, and there appear to be a number of inter-related factors that can impact 
an individual’s susceptibility to the development of these disorders, including genetic 
predisposition, the intestinal microbiome, and as of yet not fully articulated environmental 
factors. Active IBD typically results in a defect in the gastrointestinal barrier function, 
which contributes to what appears to be an inappropriate immunologic response to 
commensal bacteria (Fakhoury, 2014).    
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 The major subtypes of IBD are Crohn disease (CD) and ulcerative colitis (UC). 
While often clinically similar in presentation, these disorders and be distinguished based 
on disease location and tissue histology (Waugh, 2013).  Whereas the inflammation 
observed in patients with UC is typically contiguous and localized to the superficial lining 
of the colonic mucosa, the inflammation in patients with CD is more likely to be 
discontinuous in nature, involve the small intestine, and involve the full wall of the 
intestine.  
 
Remicade (Infliximab) Infusion Treatment 
 There are currently no cures for CD or UC, and the clinical focus is on eliminating 
symptoms, eliminating inflammation, preventing disease complication and optimizing 
patient quality of life. While patients with IBD are at risk for a number of comorbidities, 
their life expectance is typically approximate that of their IBD-free peers (Lopez San 
Roman, 2011; Fakhoury, 2014).  
 Treatment of symptoms typically involves the administration of oral and 
intravenous immunosuppressive and anti-inflammatory drugs (Fakhoury, 2014). One such 
treatment option is intravenous interval administration of Remicade. Remicade is a 
chimeric monoclonal antibody that neutralizes Tumor Necrosis Factor-a (TNF-a) in 
circulation and induces apoptosis in TNF-producing immunocytes (Guo, 2013). Remicade 
infusions can be administered every four to eight weeks, and titrated to meet clinical 
demands.  
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Objectives 
 Existing data have demonstrated the prevalence of vitamin D deficiency in patients 
with IBD, and anywhere from 16 to 95% of patients with UC and CD are vitamin D 
deficient at any given time (Del Pinto, 2015). Moreover, treatment of the underlying 
mucosal disease does not correct for vitamin D deficiency. As more is revealed about the 
diverse roles that vitamin D play, especially with respect to its support of the immune 
system, it is becoming increasingly important to monitor and maintain vitamin D 
sufficiency, especially amongst pediatric patients with IBD not only to aid in growth, but 
also to boost their immune system (Aranow, 2011; Gubatan, 2017). Nonetheless, while 
readily available in a variety of tablet, capsule, and suspension formulation, compliance 
with vitamin D therapy has been notoriously low in children and adults (Pappa, 2012). 
 This paper investigates the effects of high dosage interval vitamin D 
supplementation in children and adolescents with IBD being treated with Remicade. The 
goal is to assess the safety and efficacy of this dosing format to maintain sufficient (35-50) 
25OHD levels. Rather than require patients to take daily vitamin D supplements, patients 
enrolled in this study will receive oral vitamin D supplementation during their routine and 
scheduled Remicade infusions. This process ensures compliance. Vitamin D supplements 
are commercially available at relatively low-cost; as such this investigation will assess the 
safety and efficacy of a novel dosing format on vitamin D sufficiency in a population of 
children and adolescents with IBD. This study was approved by the Institutional Review 
Board (IRB) at Boston Children’s Hospital (Protocol # P00023836).  
 
	6 
METHODS 
Pre-Screening 
 The initial screening process involves the identification of patients between age 5 
to 25 years who carry a diagnosis of CD or UC, being treated with Remicade, and have a 
serum 25OHD level below 30.0ng/mL within 8 weeks of evaluation. Potential study 
subjects were identified through serial screening on PowerChart, the electronic medical 
record database at Boston Children’s Hospital. Initially, only patients from the Longwood 
Avenue campus of Boston Children’s Hospital were eligible for participation.  We were 
able to begin screening and enrolling subjects in the Waltham satellite starting on 
November 1, 2017. Patients were excluded if they had a history of an underlying liver or 
kidney disease that could confound analysis of adverse effects and pharmacokinetics.  
In addition, patients with a history of granulomatous disease or dysphagia were 
excluded. Patients were excluded from participation in this study at the discretion of their 
primary GI physician.  
 
Recruitment 
 Patients were recruited either during their scheduled Remicade appointments or 
during a GI clinical appointment. On the day of the approach (day 0), the study was 
explained to the patient and/or legal parent or guardian. Once the parents consented and 
the child assented to participation in the study, patients were asked to fill out the relevant 
survey materials.  
 
	7 
Interval High Dosage Vitamin D 
 Patients enrolled in the study were to be followed for one year. Patients receiving 
Remicade infusions every 4-6 weeks received 50,000 IU of oral vitamin D, and those 
receiving Remicade infusions every 6-8 weeks received 100,000 IU.  
 The DRISDOL brand (NDA #003444) of ergocalciferol capsules, which came in 
50,000IU, was used for the study. Other inactive ingredients included FD&C Blue #1, FD 
& C Yellow #5, Gelatin, Glycerin, Parabens and Soybean Oil (FDA Approved Drug 
Products, 2018).  
 
Survey & Lab Data 
Patients were also asked to fill out baseline and follow-up surveys to assess dietary 
intake of vitamin D and sun exposure. At the time of consent (Day 0), patients are asked to 
fill out the IMPACT-III (HR) instrument, a 35-item survey developed to assess health-
related quality of life amongst pediatric IBD patients (Abdovic, 2013). At the time of the 
first high dosage (Visit 1), which can be concurrent to the date of consent, patients are 
asked to fill out a Baseline Survey (Figures 1). Follow-Up Surveys were filled out during 
subsequent visits.  
Additionally, serial urine calcium and creatinine measurements were also 
performed to assess for the development of hypercalciuria and an increased risk of the 
development of renal stones. Urine samples were collected and assessed every other 
Remicade appointment. Serum 25OHD levels were also checked every other Remicade 
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appointment, starting with Visit 2. Table 1 summarizes the data collected from Day 0 
through the subsequent visits.  
 
Table 1. Data Collection Schedule. All participants were to be followed for a year. Visit 
numbers may vary since participants’ Remicade appointments were in varying intervals.  
 
ITEM	 Day	0	 Visit	1	 Visit	2	 Visit	3	 Visit	4	 Visit	5	
Consent	
Form	
X	 	 	 	 	 	
IMPACT-
III	(HR)	
X	 	 	 	 	 	
Baseline	
Surveys	
	 X	 	 	 	 	
Follow-Up	
Surveys	
	 	 X	 X	 X	 X	
High	
Dosage	
Vitamin	D	
	 X	 X	 X	 X	 X	
Serum	
25OHD	
	 	 X	 	 X	 	
Urine	
Calcium	
	 	 X	 	 X	 	
Urine	
Creatinine	
	 	 X	 	 X	 	
 
 
Case Report Forms 
 All data collected, including survey data, was then imported into Case Report 
Forms (CRFs) created on the Research Electronic Data Capture (REDcap), a HIPAA-
compliant web application. REDcap facilitated data organization, gathering and analysis.  
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Figure 1. Baseline Survey. Copy of baseline survey pages 1 through 7.   
 
 
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 1 of 7 
 
SECTION A:  GENERAL INFORMATION  
A1. Study ID Number:  ___ ___  
A2. Screening Number ___ ___  
A3. Date of Visit:   ___ ___ / ___ ___ / ___ ___ ___ ___ 
                               M    M      D     D       Y    Y    Y    Y 
A4. Date of Birth: ___ ___ / ___ ___ / ___ ___ ___ ___ 
                             M    M      D    D       Y    Y     Y     Y 
A5. Initials of person completing form: ___ ___ ___ 
 
SECTION B: MEDICAL HISTORY 
 B1. Do you have any health problems other than IBD that you are regularly treated for?  
Yes…………………………………………………………………………..1 
No………………………………………………………….........................0 (Go to question B2). 
 
B1a. What health problem(s)?  
   Asthma………………………………………………………….…1   
   Seizures……………………………………………....................2  
   Diabetes...…………………………………………………….…..3  
   Arthritis……………………………………………......................4  
   Other……………………………………………………………..99 
    B1ai. Specify: ______________________________ 
 
B2. Are you currently taking any medications, including prescription medications,  
       OTCs, vitamins, herbals?  
  Yes…………………………………………………………………………...1  
  No…………………………………………………………..........................0 (Go to question B3)  
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Figure 1 continued. 		
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 2 of 7 
 
B2a. What medication(s)?  
   Yes No 
i. Inhaled or oral steroids (Prednisone, Flovent, Advair)  1 0 
ii. Seizure medication (Depakote, Tegretol) 1 0 
iii. Vitamins (multivitamin, Viactive, Caltrate D) 1 0 
iv. Herbals 1 0 
v. Other 1 0 
vi. Specify  
    
 B3. Have you been hospitalized in the past year? 
  Yes ……………………………………………………………………….…1  
  No……………………………………………………………………………0 (Go to question B4). 
     
  B3a. Why were you hospitalized? ____________________________ 
 
 B4. Have you had surgery in the past year? 
  Yes…………………………………………………………………………...1 
  No……………………………………………………………………...…….0 (Go to question C1). 
      
  B4a. Why did you have surgery? _____________________________ 
SECTION C: RACE & ETHNICITY 
 C1. Would you say you are of Hispanic ethnicity? 
Yes …………………………………………………………………………..1 
No…………………………………………………………………………….0 
C2. Which of the following group(s) do you identify with the most? 
White…………………………………………………………………………1 
Black or African American…………………………………………………2 
Asian…………………………………………………………………………3 
Native Hawaiian or Pacific Islander………………………………………4 
American Indian or Alaskan Native………………………………………5 
Other………………………………………………………………………..99 
 C2i. Specify: _______________________________________ 
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Figure 1 continued.  
 
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 3 of 7 
 
SECTION D: SKIN SENSITIVITY & PIGMENTATION 
 D1. With regard to sensitivity to the sun, would you say you are… 
  Very sensitive to sun and always burn easily……………………………1 
  Very sensitive to sun and always burn……………………………………2 
  Sensitive to sun and burn moderately…………………………………….3 
  Moderately sensitive to sun and burn minimally…………………………4 
  Minimally sensitive to sun and rarely burn………………………………..5 
  Insensitive to sun and never burn…………………………………………6 
 
D2. With regard to your skin pigmentation and tanning, would you say you… 
Tan little or not at all, even with repeated sun exposure……………….1 
Tan minimally with repeated sun exposure………………………………2 
Tan gradually …………….…………………………………………………3 
Tan easily ……………………………………………………………………4 
Tan profusely ……………..………………………………………………...5 
Tan extremely……….……………………………………………………….6 
   
 
 
SECTION E: VITAMIN D SURVEY 
E1. In the past 30 days, how often did you have milk to drink or on cereal? This would include  
       chocolate and other flavored milks, as well as hot cocoa and lattes made with milk. Would you    
       say… 
 Never…………………………………………………………………..........1 
Rarely – less than 1x per week……………………………………………2  
Sometimes – once per week or more but less than once per day……3 
Daily – once per day……………………………………………………….4 
Multiple times per day – 2 or more times per day………………………5 
  Don’t know…………………………………………………………………- 8 
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Figure 1 continued.  
 	
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 4 of 7 
 
E2. Do you eat vitamin D fortified cereal? For example – Total, enriched rice  
       cereals, etc. 
Never…………………………………………………………………………1 
Rarely – less than 1x per week……………………………………………2 
Sometimes – once per week………………………………………………3 
Often – once per day……………………………………………………....4 
Don’t know………………………………………………………………....- 8  
 
E3. Do you eat fish? 
Yes…………………………………………………………………………...1 
No…………………………………………………………………………….0 (Go to question E4) 
 
E3a. Do you eat any of these fish? 
  Yes No Don’t 
Know 
i.  Salmon, mackerel, sardines, herring 1 0 - 8 
ii.  shellfish 1 0 - 8 
iii. Other 1 0 - 8 
iv. Specify: 
    
E3b. How often do you eat fish? 
 Less than 1 time per week……………………………………....1 
1 – 2 times per week……………………………………………..2 
 3 – 4 times per week……………………………………………..3 
 5 – 7 times per week……………………………………………..4 
 
 E4. On a typical day, how much time do you spend outside? Would you say…. 
Half an hour or less per day……………………………………………...1 
Between half an hour and 1 hour per day……………………………...2 
Between 1 and 2 hours per day…………………………………………3 (Go to question E4b). 
More than 2 hours per day………………………………………………4 (Go to question E4b). 
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Figure 1 continued.  		
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 5 of 7 
 
E4a. Of the following, what is main the reason for spending little time outside? 
Not enough time (too busy)……………………………………1 
Threat of crime or harm………………………………………..2 
No parks or facilities in the area………………………………3 
Lack of interest………………………………………………….4 
Cold/bad weather……………………………………………….5 
Other…………………………………………………………….99 
 E4ai. Specify: ______________________________ 
 
E4b. Do you wear sunscreen? 
Yes……………………………………………………….…………1 
No…………………………………………………...……………...0 
 
E4c. When outside, how exposed is your skin to the sun? 
   Minimally (face and neck)………………………………………..1 
   Moderately (arms and legs)……………………………………..2 
 Highly (bathing suit exposure) ………………………………….3 
   
 E6. Do you ever go to a tanning salon and lie in a tanning bed? 
Yes…………………………………………………………………………..1 
No……………………………………………………………………………0 (Go to question E8). 
E6a. How often?  
Once per month or less………………………………………….1 
2-3 times per month……………………………………………...2 
Once per week……………………………………………………3 
Multiple times per week……………………………………….4 
E6b. How long do you tan per session? 
 Less than 5 minutes…………………………………………...1 
 6 - 10 minutes…………………………………………………...2 
 11 - 15 minutes………………………………………………….3 
 16 minutes or more …………………………………………….4 
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Figure 1 continued.  
 	
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 6 of 7 
 
 E8. In the past 12 weeks, have you traveled outside of New England? 
Yes……………………………………………………………………….1 
  No…………………………………………………………………………0 (Go to question E9) 
 
E8a. Did you travel somewhere warm? 
Yes………………………………………………………………….1 
No ………………………………………………………………….0 
 
E8b. When outside, how exposed was your skin to the sun? 
   Minimally (face and neck)………………………………………..1 
   Moderately (arms and legs)……………………………………..2 
 Highly (bathing suit exposure) ………………………………….3 
 
E8c. How many days did you spend time in the sun? 
Less than 1 day…………………………………………………...1 
1-3 days….………………………………………………………..2 
4-6 days…………………………………………………………...3 
 7-14 days………………………………………………………….4 
 >14 days…………………………………………………………..5 
 
E8d. How many hours per day on average did you spend time in the sun?  
 <1 hour………………………………………………………….…1 
 1-3 hours……………………………………………………….….2 
 > 3 hours……………………………………………………….….3 
E8e. Did you wear sunscreen? 
Yes……………………………………………………….………...1 
No…………………………………………………...……………..0 
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Figure 1 continued.  	
 
Clinical Trial of High Dose Interval Vitamin D Supplementation in Patients with IBD 
Form 1                Baseline Data                                            Version 03/02/17 
Study ID: ___ ___ Version 03.17.09                  Page 7 of 7 
E9. In the last 2 months, did you ever take any vitamins before this study regularly (daily, weekly, 
bi-weekly)? 
Yes……………………………………………………………………………..1 
No………………………………………………………………………………0  
 
E9a. What kind of vitamins? 
    
  Yes No 
i. Multivitamin 1 0 
ii. Vitamin D supplements  1 0 
iii. Calcium supplements (including Tums) 1 0 
iv. Calcium & vitamin D supplements (Viactiv, 
Caltrate D) 
1 0 
v. Other 1 0 
vi. Specify: 
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RESULTS 
Patient Screening 
A total of 327 CD and/or UC patients receiving Remicade treatment were identified 
and subsequently screened for recruitment from the Longwood Avenue campus and the 
Waltham satellite (Figure 2).  
Of the 327 patients, 153 patients (46.8%) had serum 25OHD values recent enough 
(within 8 weeks of evaluation) to be further screened for study recruitment. Of these, 50 
patients had 25OHD levels greater than 30.0ng/mL and were subsequently excluded from 
participation in the study.  
The remaining 174 patients (53.2%) had serum 25OHD values that had been 
obtained prior to 8 weeks. The GI providers for these patients were contacted to assess the 
clinical propriety of obtaining a follow-up serum 25OHD level. Of these 174 tentative 
patients, 88 patients (26.9%) were found to have values between 8 weeks and a year old, 
while 86 patients (26.3%) had values over a year old. This value is listed as “missing data” 
in Figure 2.1 since this value became unavailable after a year. A pie chart in Figure 2.2 
summarizes the availability of 25OHD levels for the study’s pre-screening.  
103 (31.5% of total screened) patients passed onto the next round of screening, 
where they were checked for any pre-existing liver, kidney or granulomatous dysfunctions 
and diseases. 13 patients were subsequently excluded for one of these reasons. One patient 
was excluded from the study due to a cancer that may compromise the liver and/or kidney 
(Figure 2).  
	17 
 
 
Figure 2. Patient Recruitment Process. A total of 327 patients were assessed from Boston 
Children’s Hospital. Patients were recruited from BCH’s Longwood and Waltham 
locations. Patients were screened for eligibility prior to notifying their GI providers, which 
led to exclusions for various reasons. There were also post-approach and post-enrollment 
exclusions.  
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At the discretion of their respective GI physicians, 3 of the remaining 89 patients 
(27.2% of the total screened) were excluded from the study. Another 14 patients were 
excluded from the study either the clinician having already initiated vitamin D intervention 
prior to recruitment into the study or if physicians requested a greater vitamin D 
prescription than the study provided. Another 9 patients were going to be unavailable for 
serial monitoring, and this occurred when subjects were attending schools outside of the 
BCH area for majority of the year, or if it was anticipated that subjects were to be 
transferred to adult care within the next year. Another 2 patients were going to stop their 
Remicade treatment within the next year and 4 patients were excluded as they were found 
to not be good candidates (Figure 2).  
The remaining 52 patients (15.9% of the total screened) were approached and 48 
patients were consented for participation in the study. Post-approach exclusion included 
patient declines, dysphagia, and allergy. Exclusion due to allergy (n=2) was due to one 
patient being allergic to gelatin and another patient reporting to feeling nauseous after 
consumption of vitamin D.  
4 participants of the 48 were removed from the study, making for a final total of 44 
participants being analyzed in this paper. These 4 participants were removed from the study 
due to lack of compliancy with taking the vitamin D capsules.   
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Demographics of Enrolled Patients 
 Demographic information of the 44 participants is summarized in Table 2. 47.7% 
of the participants were between the ages of 15 and 20 (Figure 3). Patients older than this 
age bracket were likely being transferred to adult care and patients younger than this age 
bracket tend to have difficulty swallowing capsules. The youngest participant was age 7 
while the oldest was age 23 at their respective times of recruitment.  
 32 of the participants were male while 12 were female (Table 2). 28 of the 
participants identified as white, 7 identified as black or African American, 3 identified as 
Hispanic, and 2 identified as Asian. One patient chose the “other” choice in the survey and 
identified as Persian. 35 of the participants had Crohn disease and 9 had ulcerative colitis.  
 
Table 2. Demographics Summary. Demographic distribution of the participants. 
 
Age	(mean	±	SD)	 17.0	±	3.8	
Gender	
Female	
Male	
	
12	
32	
Ethnicity	
White	
Black	
Asian	
Hispanic	
Other	
	
28	
7	
2	
3	
1	
Disease	
CD	
UC	
	
35	
9	
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Figure 3. Age Distribution of Participants. Pictured is a distribution of the participants’ 
ages. Labeled on the horizontal axis are the dates of birth ranges, divided into five 5-year 
increments. The study recruited anyone between the ages of 5 and 25.  
 
 
 
Figure 4. BMI Distribution of Participants. Distribution of the participants’ BMIs.  
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Baseline 25OHD Levels 
The overall median serum 25OHD levels of study participants was 23.4ng/mL at 
the time of enrollment (Day 0) (Figure 5). Crohn disease participants had a slightly lower 
median of 23.1ng/mL, while ulcerative colitis participants had a median 25OHD level of 
23.7ng/mL. The lowest recorded serum 25OHD level was 10.6ng/mL, and the highest level 
recorded was 29.6ng/mL. Note that the larger range shown for participants with Crohn 
disease in Figure 4 could be due to the fact that 35 out of the 44 of the participants had 
Crohn disease.  
 
Figure 5. Baseline Serum 25OHD Levels of Participants at Time of Enrollment. 
Patients with serum 25OHD levels below 30.0ng/mL were qualified for this study. The 
median serum 25OHD value was 23.1ng/mL for Crohn disease patients and 23.7ng/mL for 
ulcerative colitis patients.  		
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Assessing Health-Related Quality of Life in Study Participants: IMPACT-III (HR) 
The IMPACT-III (HR) instrument assesses the health-related quality of life in 
pediatric IBD patients. The participants in this study had an average score of 142.0 ± 18.8, 
corresponding with mild disease activity. The survey has questions categorized into 6 
domains. Each question can receive a score on a scale of 1-5. Higher scores correlate with 
better quality of life and lower scores correlate with worse quality of life.  The average 
scores of each domain amongst the 44 participants are listed in Table 3.   
 
Table 3. IMPACT-III (HR) Scores. This survey was created by a Canadian research 
group in 1999 (then called IMPACT-I) to assess the health-related quality of life amongst 
children and adolescents with IBD (Griffiths, 1999). The 35-question survey has 6 main 
categories whose questions are scattered randomly throughout the survey.  
 
 
	 Mean	Score	 Mean	Scaled	Score	(%)	
IBD	Symptoms	 28.4	±	4.4	 81.1	±	12.6	
Systemic	Symptoms	 11.4	±	2.4	 76.0	±	16.0	
Emotional	Functioning	 27.8	±	5.6	 79.4	±	16.0	
Social	Functioning	 50.4	±	6.4	 84.0	±	10.7	
Body	Image	 11.3	±	2.1	 75.3	±	14.0	
Treatments	and	Interventions	 12.7	±	1.8	 84.7	±	12.0	
TOTAL	SCORE	 142.0	±	18.8	 81.1	±	10.7	
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Assessing Pre-Study Sources of Vitamin D Among Study Participants 
 The baseline surveys assessed the participants’ sources of vitamin D (Figure 6). 
20.5% of participants responded that they rarely or never consumed milk daily. 31.8% of 
participants responded that they consume milk a few times per week, but not daily. 38.6% 
of participants responded that they consume milk at least once per day. 47.7% of 
participants responded that they never consumed vitamin D-fortified cereal and 46% of 
participants responded that they never consumed seafood high in vitamin D.  
Participants who reported consumption of least one of the vitamin D-enriched 
foods, (dairy, vitamin-D fortified cereal, seafood), made up 93.2% of the study (Figure 7). 
47.7% of the participants responded to consuming at least one of three foods. 29.5% 
responded to consume two of three foods while 9.1% of the participants responded to 
consume all three foods.  
Figure 8 shows the participant response to whether they have taken any 
multivitamins or vitamin D supplements within the last 2 months. 25% of the participants 
responded to have taken vitamins within the last 8 weeks. Note that all patients consented 
for the study have serum 25OHD levels below 30.0ng/mL checked within the last 8 weeks 
and have no high dosage vitamin D interventions, even if they have taken supplements.  
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Figure 6. Baseline Data: Participants’ Sources of Vitamin D from Food. The figures 
show the distribution of responses to the baseline question regarding consumption of foods 
(a) Consumption of Dairy 
 
 
(b) Consumption of Vitamin D-Fortified Cereal 
 
 
(c) Consumption of Seafood High in Vitamin D 
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high in vitamin D. (a) Consumption of Dairy. 20.5% of participants responded that they 
rarely or never consumed milk daily. 31.8% of participants responded that they consume 
milk a few times per week, but not daily. 38.6% of participants responded that they 
consume milk at least once per day. (b) Consumption of Vitamin D-Fortified Cereal. 
47.7% of participants responded that they never consume vitamin D-fortified cereal and 
13.6% of patients were unsure of whether they have. 4.5% of the participants responded 
that they eat vitamin D-fortified cereal once a day. (c) Consumption of Seafood High in 
Vitamin D – 54% of patients responded that they consume seafood high in vitamin D. 
These included salmon, mackerel, sardines, herring and shellfish.  
 
 
 
 
Figure 7. Baseline Data: Participants Consuming Dairy, Vitamin D-Fortified Cereal 
and/or Seafood High in Vitamin D. The following pie chart merges the survey responses 
for consumption of dairy, vitamin D-fortified cereals and seafood high in vitamin D.  
 
 
 
6.8%	None	of	the	
Three
47.7%	One	of	the	
Three
29.5%	Two	of	
the	Three
9.1%	All	Three
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Figure 8. Baseline Data: Consumption of Vitamin D Supplements. This figure shows 
the distribution of responses to whether participants have taken multivitamins and/or 
vitamin D supplements within the last 2 months of taking the survey.  
 
 The second source of vitamin D, sunlight exposure, was also assessed in the 
baseline surveys. 58.4% of study participants responded to having 1 hour or less of sunlight 
exposure per day (Figure 9, (a)).  61.0% of study participants reported to use sunscreen on 
a daily basis (Figure 9, (b)). Of the participants who reported have 1 hour or less of sunlight 
exposure, 66.7% reported to have regularly use sunscreen.  
 Both the baseline and follow-up surveys ask participants whether they’ve travelled 
outside of New England in the last 12 weeks to somewhere warm. 12.2% of study 
participants reported to have traveled outside of New England to somewhere warm at the 
start of their participation (Figure 9, (c), (d)).  
 
 
0 5 10 15 20 25 30 35
Yes
No
Number	of	Participants
Respon
se
	27 
Figure 9. Baseline Data: Exposure to Sunlight. The following four figures show the 
responses to how often the participants were exposed to sunlight. (a) Daily Sunlight 
(a) Daily Sunlight Exposure 
	
 
(b) Daily Sunscreen Wear 
	
 
(c) Travel Outside of New England 
 
 
(d) Travel Outside of New England to Somewhere Warm 
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Exposure. The graph is based on the baseline question asking on average how often the 
participant spends on a typical basis outdoors. 58.5% reported to have spent one hour or 
less time outside. Another 26.8% of participants reported to have spent time between one 
and two hours outdoors. (b) Daily Sunscreen Wear. The graph is based on a baseline 
question that follows-up on the question regarding daily sunlight exposure and asks 
whether the participant wears sunscreen daily. 61.0% of participants reported to wear 
sunscreen regularly. (c) Travel Outside of New England. The graph is based on the 
baseline question asking whether participants have traveled outside of New England within 
the past 12 weeks. (d) Travel Outside of New England to Somewhere Warm. The graph 
is based on a baseline question that follows-up on the previous question regarding travel 
outside of New England and asks whether the travel was to somewhere warm. 50% of those 
that travelled went somewhere warm.   
 
Serum 25OHD Level Changes After High Dosage Treatment 
 Study participants still have more interval high doses of vitamin D to take in the 
next few months as of March 5, 2018. As of that date, there are 10 participants that have 
reached to at least their second high-dosage treatment. Serum 25OHD levels are assessed 
during the second visit and every other visit thereafter. All ten participants that have 
reached this stage of the study are Crohn disease patients. Overall, their median serum 
25OHD levels increased by 5.35ng/mL, reaching a level of 28.45ng/mL (Figure 10). Note 
that this is still not above the recommended serum 25OHD level of 30.0ng/mL.  
 The line drawings for these ten participants are individually graphed in Figure 11. 
The majority of the participants had an increase in their serum 25OHD levels. At the time 
of enrollment, the average serum 25OHD was 20.76ng/mL. Their serum 25OHD levels 
during the second visit increased to 26.62ng/mL.  
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*p<0.05 (p = 0.02) 	
Figure 10. Serum 25OHD Levels Over Time in CD Patients on Interval High Dose 
Vitamin D. Serum 25OHD Levels were measured for the first-time post-enrollment during 
the patient’s second Remicade appointment. This is during the beginning of the visit after 
the patient has taken the first oral interval high dose vitamin D. The median value during 
the second visit was 28.45ng/mL in CD patients. This is a 5.35ng/mL increase from the 
baseline median serum 25OHD value of 23.1ng/mL.*  													
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*p<0.05 (p = 0.02) 
 
Figure 11. Serum 25OHD Levels Over Time in CD Patients on Interval High Dose 
Vitamin D (Individuals). Shown is a line graph of each individual enrolled patient’s serum 
25OHD levels over time. At the time of enrollment, the average serum 25OHD was 
20.76ng/mL. During the second visit, after the first high dose vitamin D, the average serum 
25OHD was 26.62ng/mL.* 
 
 Further assessment of the participants was done, as shown in Figure 12 and Figure 
13. The ten participants were separated into two categories, depending on the interval of 
their Remicade appointment, and hence their high dosage vitamin D administrations. One 
category was participants who have their Remicade infusions every 4 or every 8 weeks. 
The other category was participants who have their Remicade infusions every 5 or 6 weeks. 
These categories also correspond to average aggregate dose of vitamin D that these 
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participants would receive. The study provides patients whose Remicade appointments are 
every 4-6 weeks with 50,000 IU and those whose visits are every 6-8 weeks with 100,000 
IU. In other words, those whose visits are exactly every 4 or every 8 weeks, would receive 
on average 2000 IU of vitamin D daily. Those whose visits were every 5 or 6 weeks would 
receive on average less than 2000 IU of vitamin D daily. Note that although none of these 
ten participants had appointments every 7 weeks, dividing 100,000IU over the course of 7 
weeks or 49 days would mean participants would be receiving on average more than 
2000IU daily.  
 As shown in Figure 12, those who received on average 2000 IU of daily vitamin D 
had a 25OHD level of 30.5ng/mL during their second visit, just surpassing the 
recommended minimum level. This is a 46.9% increase in 25OHD level from the average 
starting value of 20.76ng/mL. In comparison, those who receive on average less than 2000 
IU of daily vitamin D had a serum 25OHD level of 20.83ng/mL during the second visit 
(Figure 13). This is just a 0.34% increase in serum 25OHD level from the starting average 
of 20.76%. Figures 12 and 13 illustrate how the overall average serum 25OHD levels of 
the participants did not increase to the optimal level of 30.0ng/mL. Figure 14 compares the 
data from Figures 12 and 13.  
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p = 0.092 
 
Figure 12. Serum 25OHD Levels Over Time in CD Patients on Interval High Dose 
Vitamin D (Q4, Q8). Shown is the data for patients who are receiving their interval high 
dose vitamin D every 4 or every 8 weeks. Those visiting every 4 weeks received 50,000 
IU and those visiting every 8 weeks received 100,000 IU. In other words, these patients 
received 2000 IU daily. The average serum 25OHD increased to 30.5ng/mL from 
20.76ng/mL in these patients.  
 
 
 
p = 0.271 
Figure 13. Serum 25OHD Levels Over Time in CD Patients on Interval High Dose 
Vitamin D (Q5, Q6). Shown is the data for patients who are receiving their interval high 
dose vitamin D every 5 or every 6 weeks. These patients received 50,000 IU of vitamin D. 
In other words, these patients received less than 2000 IU daily. The average serum 25OHD 
increased to 20.83ng/mL from 20.76ng/mL in these patients. 
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Figure 14. Average Serum 25OHD Levels Over Time in CD Patients: Q4, Q8 vs. Q5, 
Q6. A comparison of patients receiving high dose vitamin D every 4 or 8 weeks to every 
5 or 6 weeks. In other words, this is a comparison of patients receiving on average 2000 
IU daily of vitamin D and less than 2000 IU daily of vitamin D. This data suggests that CD 
and UC patients receiving 2000 IU daily of vitamin D would get at least a 25OHD level of 
30ng/mL.  
 
 
Table 4. BMI Values and Serum 25OHD Levels Over Time of Individual Participants. 
Displayed are the BMI values, serum 25OHD levels on Day 0 and serum 25OHD levels 
on Visit 2 of each individual participant. The final column displays the change in serum 
25OHD levels over time for each individual. Mean values are also displayed 
 
	
BMI	(kg/m2) 
Day	0	
Serum	25OHD	
(ng/mL) 
Visit	2	
Serum	25OHD	
(ng/mL) 
∆	
(ng/mL) 
	 15.8 25.4 32.3 6.9 
	 16.0 22.3 29.9 7.6 
	 17.5 27.2 32.3 5.1 
	 17.9 25.9 30.7 4.8 
MEAN	±	SD	 16.8	±	1.1 25.2	±	2.1 31.3	±	1.2 6.1	±	1.4 
	 25.9	 10.6	 21.9	 11.3	
	 26.9	 23.1	 30.7	 7.6	
	 27.2	 22.5	 27.0	 4.5	
	 29.0	 22.2	 19.7	 -2.5	
	 29.1	 11.6	 23.3	 11.7	
	 32.2	 16.8	 18.4	 1.6	
MEAN	±	SD	 28.4	±	2.2	 17.8	±	5.7	 23.5	±	4.6	 5.7	±	5.6	
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*p = 0.22 **p = 0.40 
 
Figure 15. Serum 25OHD Level Over Time Between Underweight BMI and 
Overweight BMI. Of the 10 participants, 4 had BMI values ranging from 15.8 to 
17.9kg/m2 while 6 had BMI values ranging from 25.9 to 32.2 kg/m2. The mean BMI 
values are respectively 16.8kg/m2 and 28.4kg/m2. 
 
 
 The serum 25OHD levels were then compared to the BMI values. Shown in Table 
4 were the BMI values, serum 25OHD levels on Day 0 and serum 25OHD levels on Visit 
2 of the 10 individual participants. The final column lists out the changes in the serum 
25OHD levels from Day 0 to Visit 2. Each participant’s BMI can be characterized as 
being underweight or overweight. Of the 10 participants, 4 had BMI values ranging from 
15.8 to 17.9kg/m2 while 6 participants had BMI values from 25.9 to 32.2kg/m2. The 
mean BMI values were respectively 16.8kg/m2 and 28.4kg/m2.  
Interestingly, the change in serum 25OHD levels of those in the underweight 
group (6.1ng/mL with a standard deviation of 1.4ng/mL) were more consistent across 
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individuals. In contrast, there was a more modest change in serum 25OHD levels in the 
overweight group (5.7ng/mL with a standard deviation of 5.6ng/mL).  
 Data illustrated in Figure 15 compares the serum 25OHD levels over time in 
underweight and overweight study participants. The slopes of the 16.8kg/m2 BMI and 
28.4kg/m2 BMI are noticeably comparable and the change in serum 25OHD is 6.1kg/m2 
and 5.7kg/m2 respectively. However, as noted in Table 4, the variation in serum 25OHD 
changes was much greater in the overweight group than in the underweight group, which 
was more stable. The p-values for both data sets for the underweight and overweight 
group were both greater than 0.05.   
 
Hypercalciuria Check 
 The participants’ spot urine calcium to creatinine ratios were checked every other 
visit starting with Visit 2. Vitamin D increases intestinal calcium absorption.  Urine 
calcium or urine creatinine ratios larger than 0.2 suggest hypercalciuria. As shown in the 
last column in Table 5, all calcium to creatinine ratios of the participants were lower than 
0.2.  
Table 5. Urine Calcium to Creatinine Ratios. Urine calcium and creatinine values were 
routinely checked in order to monitor for hypercalciuria. 
 
Urine	Calcium		
(mg/dL) 
Urine	Creatinine	
(mg/dL) Calcium/Creatinine 
20.6 365.7 0.06 
5.4 54.6 0.10 
13.8 371.4 0.04 
5.0 289.9 0.02 
10.3 294.5 0.03 
2.6 80.0 0.03 
20.3 129.1 0.16 
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DISCUSSION 
 Of the 327 patients screened, 153 (46.8%) had serum 25OHD values within 8 weeks 
of evaluation. Of these 153 patients, there was roughly a 2:1 ratio of patients with serum 
25OHD values lower than 30.0ng/mL. The remaining 174 patients have serum 25OHD 
values older than 8 weeks upon time of evaluation. Of these, 86 patients had values over a 
year old. This data suggests that there are likely to be patients with IBD and vitamin D 
deficiency that go unnoticed. It further supports the hypothesis that treating the IBD is not 
sufficient to result in vitamin D sufficiency (Ahlawat, 2017).  
 Furthermore, based on the baseline survey responses, 93.2% of the participants 
responded that they consume at least one of three vitamin D-enriched foods, dairy, vitamin-
D fortified cereal or seafood. Even if these patients are consuming vitamin D-enriched 
foods, since 9.1% of the patients responded that they consume all three on a regular basis, 
they were still found to be vitamin D insufficient, since these are patients that met the 
requirements for enrollment into the study. 80.4% of the participants responded that they 
have taken vitamin D within the 2 months since study enrollment. Thus, simply 
recommending multivitamin or vitamin D supplementation to patients with IBD is unlikely 
to be successful to vitamin D sufficiency.  
 58.5% of participants responded that they spend one hour or less per day outdoors, 
with a majority providing the reason as due to the cold weather or lack of interest. 
Moreover, 61.0% of these participants wear sunscreen on a regular basis, which blocks the 
UV rays from penetrating the skin to produce the necessary chemical reactions to produce 
vitamin D. These participants reside in the New England area and thus get less sun exposure 
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both due to more cloudy days and colder weather leading many to stay indoors. Without 
sunlight, the natural source of vitamin D, patients have to be able to get their vitamin D 
elsewhere.  Note that data reported in this thesis was drawn primarily between the months 
of October and March, which is during the colder seasons in Boston.  
 The average IMPACT-III (HR) score of the participants was 142.0 ± 18.8, which 
corresponds to mild disease activity (Abdovic, 2013). Note that with all of these surveys, 
there is the potential for the introduction of self-reporting or proxy-reporting bias. Pediatric 
patients often come in with a parent or guardian to their Remicade appointments, which 
can influence how they may respond to quality of life questions. Since the surveys have 
identifiable information, the participant responses may also be influenced by the 
knowledge that researchers can identify the responses (Grant, 2017).  
The final list of 44 participants consisted of 35 patients with Crohn disease and 9 
patients with ulcerative colitis. The difference in distribution in these IBD patients is due 
to the fact that the study looks for IBD patients receiving Remicade infusion. The study is 
leveraging the regular 4-8 weeks Remicade infusion appointments in order to provide the 
IBD patients with vitamin D. Interestingly, although IBD is more prevalent in females than 
in males, the study was recruited 12 female patients and 32 male patients. The ethnic 
demographics are more consistent with the general demographics of Boston and 
neighboring towns.  
The study recruited male and female subjects with IBD between the ages of 5 and 
25. However, since the study was providing vitamin D capsules, there were limitations 
with respect to dysphagia and an inability to swallow capsules. Overall, 75% of the 
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participants were between the ages of 15 and 25, with 47.7% of the participants being over 
the age of 18. Participants in this older age bracket appeared noticeably more open to 
listening to the research study. Several patients who were of college age, between 18 and 
22 years old, were also noticeably quicker to agree to participation in the study due to their 
own personal past experiences with clinical research.    
 Ten participants as of March 5, 2018 reached visit 2 of the study schedule, which 
is also the first time serum 25OHD levels were measured after the first high-dosage of oral 
vitamin D. These serum 25OHD levels were taken prior to taking their second high-dosage 
of oral vitamin D. The average serum 25OHD level at the time of enrollment was 
20.76ng/mL. The average serum 25OHD level measured during visit 2 was 26.62ng/mL, a 
5.86ng/mL increase. The p-value for this change is 0.02, making it a significant increase 
in serum 25OHD level. These data are further illustrated in Figure 11. The trend has 
generally been an increase in serum 25OHD level, in response to per protocol treatment.  
 These data was divided into two sets in an effort to complete further analysis. This 
division is based on the observation that patients were given different amounts of vitamin 
D depending on the interval of their Remicade appointment. As mentioned, those who had 
Remicade appointments every 4-6 weeks were given 50,000 IU of oral vitamin D. 
However, this meant that participants who had their appointments every 5 or every 6 weeks 
also received 50,000 IU of oral vitamin D coincident with their infusions. Vitamin D can 
be stored in the body and note that vitamin D half-life is on average 2 weeks (Jones, 2014). 
Nonetheless, by dividing 50,000 IU of vitamin D over the course of 5 or 6 weeks, some 
enrolled participants were receiving on average less than 2000IU/day of vitamin D. The 
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patients’ normal everyday intake or production of vitamin D was not enough to provide 
them with sufficient vitamin D levels, so the provision of oral vitamin D supplementation 
at a recommended daily dose of 2000 IU would be important. Patients who had 
appointments every 4 or every 8 weeks received 50,000 IU and 100,000 IU of oral vitamin 
D respectively, which averages out to 2000 IU of vitamin D daily.  
 As shown in Figure 12, those participants received high dosage vitamin D every 4 
or every 8 weeks had an average 25OHD level of 30.5ng/mL during the second visit. This 
is a 9.74ng/mL increase in serum 25OHD. Due to an even smaller sample size of six 
participants, this is not considered significant, as the p-value was equal to 0.092. However, 
participants who received high dosage vitamin D every 5 or 6 weeks had an average 
25OHD level of 20.83ng/mL, which represents only a 0.07ng/mL increase from their 
baseline level (Figure 13).  
A possible explanation is that patients have exhausted their vitamin D stores that 
they received from the high-dosage vitamin D capsules and have now returned to their 
baseline serum 25OHD levels. Due to small sample size, this can only be speculated, as 
the p-value for this sample was 0.27. Moreover, as show in Figure 13, only one participant 
had before and after serum 25OHD levels remain roughly steady, while the other samples 
decreased or had a large increase in their 25OHD levels.  
As shown in Figure 13, there was one participant whose serum 25OHD level fell in 
response to study drug therapy. This can be the result of a number of reasons, including 
changes in diet and temporary changes in environment (travelling to areas with even less 
sunlight). In fact, this should be noted of all study participants. Although all study 
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participants were given surveys to fill out during their high-dosage visits in order to try to 
elucidate any unusual data, lifestyle changes in the time period between the visits cannot 
be accounted for. That said, this decrease in 25OHD level is an occurrence in just one 
participant so far and thus its significance has yet to be determined.  
 The average serum 25OHD level for those receiving high doses every 4 or 8 weeks 
is 30.5ng/mL. Of these, two participants still had serum 25OHD levels lower than 
30.0ng/mL. Supplying patients coming in every 4, 5, or 6 weeks with doses higher than 
50,000IU but still lower than 100,000IU is something that can be considered in order to try 
to increase these participants with higher serum 25OHD levels. However, those coming in 
every 8 weeks but are still not achieving a serum 25OHD level of at least a measure of 
30.0ng/mL serum 25OHD would have to be given more than 100,000 IU of oral vitamin 
D during their Remicade appointmenst. Although there appear to be very few adverse 
effects associated with the provision of very high doses of vitamin D, caution still should 
be taken when providing greater doses than 100,000IU.  
There were two patients prior to enrollment into the study who reported having 
allergic reactions toward taking oral vitamin D capsules. One of the patients was allergic 
to gelatin, an ingredient in the capsule, while the other patient reported to feeling nauseous 
upon taking vitamin D. In addition, many young pediatric patients have difficulty 
swallowing capsules or tablets. This suggests that a logical extension of the study would 
be to make study drug (vitamin D) available in a liquid formulation. 
Further subgroup analysis included an assessment of the impact of body as 
demonstrated in Figure 15. Underweight is categorized as BMI values between 15-
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19.9kg/m2 and overweight is categorized as BMI values between 25-29.9kg/m2 (Nuttall, 
2015). One participant had a BMI of 32.3kg/m2, placing them in the pre-obesity category. 
The first observation, as shown in Table 4, is that changes in serum 25OHD values in 
overweight participants were more widely disperse, with a standard deviation of 5.6ng/mL, 
as compared to those observed in underweight patients, with a standard deviation of 
1.4ng/mL. The second observation is, however, that the average change in serum 25OHD 
levels was comparable in underweight and overweight cohorts (6.1 and 5.7ng/mL, 
respectively). The third observation from this data is that both average serum 25OHD 
levels measured on Day 0 and at Visit 2 for the overweight group were lower those recorded 
for the underweight group. The underweight group had an average serum 25OHD level of 
25.2ng/mL on Day 0, which increased to 31.3ng/mL on Visit 2. The overweight group had 
an average serum 25OHD level of 17.8ng/mL on Day 0, which increased to 23.5ng/mL on 
Visit 2.  
What these data may be suggesting is that patients with greater BMI’s, and likely 
greater percent body fat, sequester more of their vitamin D outside of the bloodstream, 
thereby limiting the supply to other parts of the body (Ekwaru, 2014). The greater variation 
in serum 25OHD levels, as shown by the standard deviation of 5.7ng/mL and 4.6ng/mL on 
Day 0 and Visit 2 respectively, in the overweight group, also suggests that greater percent 
body fat may result in greater fluctuations in serum 25OHD levels on a day to day basis 
(Ekwaru, 2014).  
This data therefore suggests that vitamin D dosages may be prescribed based on 
body weight and not age (Ekwaru, 2014).  However, more data and future studies will be 
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necessary to better discern relationship between percent body fat and optimal vitamin D 
dosage.  
Existing data demonstrate that many patients with IBD are vitamin D deficient (Del 
Pinto, 2015). This deficiency may be the result of lifestyle alterations due to IBD rather 
than due to small bowel malabsoprtion. Both Crohn disease and ulcerative colitis can affect 
the distal portion of the small intestines and the colon. However, the majority of our 
nutritional intake is absorbed in the duodenum, the proximal end of the small intestines.  
Whether or not vitamin D deficiency is a risk factor for the development of IBD 
remains uncertain. Nonetheless, existing data suggest that vitamin D sufficiency is 
important to maintain the immune system, help reduce inflammation and protect against 
colon cancer. Remicade appointment provide is an excellent opportunity to both assess and 
treat patients with vitamin D. Compliance with daily oral medications can be a problem, 
and efforts to define pill-sparing dosing regimens should improve overall compliance, 
patient satisfaction, and clinical outcome.     
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CONCLUSION 
 The goal of this study was to try to assess the safety and efficacy of a novel dosing 
format for vitamin administration in pediatric patients with IBD. Specifically, contact 
during Remicade appointment was leveraged to ensure compliance. Data collected in this 
study suggest that administration of serial vitamin D doses will result in an increase in 
levels. However, the data also suggest that vitamin D dosing regimens may need further 
modifications for patients who are receiving Remicade infusions every 5 or 6 weeks. 
Providing high dose vitamin D during routine Remicade appointments would only would 
not only improve patient compliance, but may also contribute to improved skeletal and 
overall GI health outcomes.   
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